(Photo Courtesy: www.mayacaceres.com)
The company's latest report states that this significant growth comes despite patent expiration of Temodar (temozolomide) and will be driven primarily by the market entry of DCVax-L vaccine.
This follows clinical trials showing that DCVax-L produces an Overall Survival (OS) of around 2.3 times longer than the current standard of care for newly diagnosed patients.
Ms Angel Wong, analyst, GBI Research, says, "The current standard treatment of surgery, radiotherapy and chemotherapy, in combination with Temodar, has an OS of less than 15 months. As DCVax-L has been shown to extend OS substantially, the vaccine will demand a premium price once it hits the market."
GBI Research expects DCVax-L, which has recently received early approval in Germany, to be approved in the US and EU in 2015 and 2016, respectively, ahead of less efficacious treatments Cotara and Rindopepimut (CDX-110), which will enter the global GBM treatment market in 2016 and 2017, respectively.
DCVax-L has the added advantage of facing few other active competitors in the current GBM therapeutics market, an investment which is regarded as high-risk.